RTOG-0912

Terminated

Return to Protocol Table

A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer

Principal Investigator

Eric Sherman

Status

Terminated

Temporarily Closed to Accrual

October 23, 2013

Open to Accrual

October 23, 2013

Open to Accrual

June 23, 2014

Closed to Accrual

December 30, 2016

Closed to Accrual & Treatment

March 8, 2017

Terminated

May 20, 2022


Disease Site

Head and Neck [HN] Head and Neck

Phase

II

Developmental Therapeutics

No

Primary Objective

To evaluate the safety of IMRT, paclitaxel, and pazopanib suspension

To evaluate and compare overall survival at 1 year from study registration.

Patient Population

Pathologically (histologically or cytologically) proven diagnosis of anaplastic thyroid cancer (a diagnosis that is noted to be “consistent with anaplastic thyroid cancer” with the presence of a thyroid mass is acceptable)

The Phase II Component is open to accrual.

Target Accrual

88

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.